Erythrocyte-Bound Apolipoprotein B in Relation to Atherosclerosis, Serum Lipids and ABO Blood Group

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Klop, Boudewijn ^a   van de Geijn, Gert Jan M ^a   Bovenberg, Sarah A ^a   van der Meulen, Noëlle ^a   Elte, Jan Willem F ^a   Birnie, Erwin ^b   Njo, Tjin L ^a   Janssen, Hans W ^a   van Miltenburg, Addy ^a   Jukema, J Wouter ^c   Cabezas, Manuel Castro ^a  

^a SINT FRANCISCUS GASTHUIS   (Netherlands)

^b Leiden University Medical Center ^*  (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ERYTHROCYTE BOUND APOLIPOPROTEIN B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD GROUP A; BLOOD GROUP AB; BLOOD GROUP ABO SYSTEM; BLOOD GROUP B; BLOOD GROUP O; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIPID BLOOD LEVEL; LIPOPROTEIN DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; APOLIPOPROTEINS B; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; ERYTHROCYTES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PHENOTYPE;

EID: 84884402489     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075573     Document Type: Article

References (24)

1. Ross R, (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126.
2. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, et al. (1996) Apolipoprotein a-i and b levels and the risk of ischemic heart disease during a five-year follow-up of men in the quebec cardiovascular study. Circulation 94: 273-278.
3. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, et al. (2012) Association of ldl cholesterol, non-hdl cholesterol, and apolipoprotein b levels with risk of cardiovascular events among patients treated with statins: A meta-analysis. JAMA 307: 1302-1309.
4. Mora S, Rifai N, Buring JE, Ridker PM, (2008) Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 118: 993-1001.
5. Verseyden C, Meijssen S, Castro Cabezas M, (2004) Effects of atorvastatin on fasting plasma and marginated apolipoproteins b48 and b100 in large, triglyceride-rich lipoproteins in familial combined hyperlipidemia. J Clin Endocrinol Metab 89: 5021-5029.
6. Bovenberg SA, Alipour A, Elte JW, Rietveld AP, Janssen JW, et al. (2010) Cell-mediated lipoprotein transport: A novel anti-atherogenic concept. Atheroscler Suppl 11: 25-29.
7. Alipour A, van Oostrom AJ, Izraeljan A, Verseyden C, Collins JM, et al. (2008) Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 28: 792-797.
8. Gower RM, Wu H, Foster GA, Devaraj S, Jialal I, et al. (2011) Cd11c/cd18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 31: 160-166.
9. van Oostrom AJ, van Wijk J, Castro Cabezas M, (2004) Lipaemia, inflammation and atherosclerosis: Novel opportunities in the understanding and treatment of atherosclerosis. Drugs 64Suppl 2: 19-41.
10. Hinderling PH, (1997) Red blood cells: A neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 49: 279-295.
11. Hui DY, Noel JG, Harmony JA, (1981) Binding of plasma low density lipoproteins to erythrocytes. Biochim Biophys Acta 664: 513-526.
12. Hui DY, Harmony JA, (1979) Interaction of plasma lipoproteins with erythrocytes. I. Alteration of erythrocyte morphology. Biochim Biophys Acta 550: 407-424.
13. Hung KT, Berisha SZ, Ritchey BM, Santore J, Smith JD, (2012) Red blood cells play a role in reverse cholesterol transport. Arterioscler Thromb Vasc Biol 32: 1460-1465.
14. Bovenberg SA, Klop B, Alipour A, Martinez-Hervas S, Westzaan A, et al. (2011) Erythrocyte-associated apolipoprotein b and its relationship with clinical and subclinical atherosclerosis. Eur J Clin Invest.
15. Sarnak MJ, Tighiouart H, Manjunath G, MacLeod B, Griffith J, et al. (2002) Anemia as a risk factor for cardiovascular disease in the atherosclerosis risk in communities (aric) study. J Am Coll Cardiol 40: 27-33.
16. Sasak WV, Lown JS, Colburn KA, (1991) Human small-intestinal apolipoprotein b-48 oligosaccharide chains. Biochem J 274 (Pt 1): 159-165.
17. Oliver MF, Geizerova H, Cumming RA, Heady JA, (1969) Serum-cholesterol and abo and rhesus blood-groups. Lancet 2: 605-606.
18. Langman MJ, Elwood PC, Foote J, Ryrie DR, (1969) Abo and lewis blood-groups and serum-cholesterol. Lancet 2: 607-609.
19. Garrison RJ, Havlik RJ, Harris RB, Feinleib M, Kannel WB, et al. (1976) Abo blood group and cardiovacular disease: The framingham study. Atherosclerosis 25: 311-318.
20. Wong FL, Kodama K, Sasaki H, Yamada M, Hamilton HB, (1992) Longitudinal study of the association between abo phenotype and total serum cholesterol level in a japanese cohort. Genet Epidemiol 9: 405-418.
21. George VT, Elston RC, Amos CI, Ward LJ, Berenson GS, (1987) Association between polymorphic blood markers and risk factors for cardiovascular disease in a large pedigree. Genet Epidemiol 4: 267-275.
22. Zhang H, Mooney CJ, Reilly MP, (2012) Abo blood groups and cardiovascular diseases. Int J Vasc Med 2012: 641917.
23. Carpeggiani C, Coceani M, Landi P, Michelassi C, L'Abbate A, (2010) Abo blood group alleles: A risk factor for coronary artery disease. An angiographic study. Atherosclerosis 211: 461-466.
24. He M, Wolpin B, Rexrode K, Manson JE, Rimm E, et al. (2012) Abo blood group and risk of coronary heart disease in two prospective cohort studies. Arterioscler Thromb Vasc Biol 32: 2314-2320.